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Abstract
Pancreatic acinar cells AR42J-B13 can transdifferentiate into hepatocyte-like cells permissive for efficient hepatitis B virus
(HBV) replication. Here, we profiled miRNAs differentially expressed in AR42J-B13 cells before and after transdifferentiation
to hepatocytes, using chip-based microarray. Significant increase of miRNA expression, including miR-21, miR-22, and miR-
122a, was confirmed by stem-loop real-time PCR and Northern blot analyses. In contrast, miR-93, miR-130b, and a number of
other miRNAs, were significantly reduced after transdifferentiation. To investigate the potential significance of miR-22 in
hepatocytes, we generated cell lines stably expressing miR-22. By 2D-DIGE, LC-MS/MS, and Western blot analyses, we
identified several potential target genes of miR-22, including parathymosin. In transdifferentiated hepatocytes, miR-22 can
inhibit both mRNA and protein expression of parathymosin, probably through a direct and an indirect mechanism. We
tested two computer predicted miR-22 target sites at the 39 UTR of parathymosin, by the 39 UTR reporter gene assay.
Treatment with anti-miR-22 resulted in significant elevation of the reporter activity. In addition, we observed an in vivo
inverse correlation between miR-22 and parathymosin mRNA in their tissue distribution in a rat model. The phenomenon
that miR-22 can reduce parathymosin protein was also observed in human hepatoma cell lines Huh7 and HepG2. So far, we
detected no major effect on several transdifferentiation markers when AR42J-B13 cells were transfected with miR-22, or
anti-miR-22, or a parathymosin expression vector, with or without dexamethasone treatment. Therefore, miR-22 appears to
be neither necessary nor sufficient for transdifferentiation. We discussed the possibility that altered expression of some
other microRNAs could induce cell cycle arrest leading to transdifferentiation.
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Introduction
Transdifferentiation from one differentiated cell type to another
can occur in vivo and in vitro. For example, hepatic foci can be
found within pancreas in experimental animal models and human
patients [1,2]. AR42J-B13 is a rat pancreatic acinar cell line,
which can transdifferentiate into hepatocytes by treatment with
dexamethasone (Dex) and oncostatin M (OSM) [3]. Transdiffer-
entiated hepatocytes of AR42J-B13 cells expressed several liver-
specific markers and transcription factors [3,4]. Interestingly, these
rodent hepatocyte-like cells can support very efficient cross-species
replication of human hepatitis B virus – a hepatotropic virus [3–5].
Recently, microRNAs (miRs) were found to regulate many
important biological processes including tumorigenesis and
development [6,7]. MicroRNAs can inhibit gene expression
through base-pairing of their seed sequences to the 39UTR of
target genes, leading to translational suppression or mRNA
degradation. However, whether miRNAs could play a role in
hepatic transdifferentiation remains to be investigated.
The expression of tissue specific miRNAs is often regulated at
the transcription level by tissue specific transcription factors (for
examples, miR-122a by HNF4, miR-192 and miR-194 by HNF1
[8,9]. Furthermore, liver specific miR-122a has been reported to
regulate many genes involved in cholesterol and fatty-acid
metabolism [9–11]. Therefore, to identify differentially expressed
miRNAs is an important approach to a better understanding of
the roles of miRNAs during transdifferentiation. Here, we profiled
the expression levels of miRNAs before and after transdifferentia-
tion of AR42J-B13 cells by microarray analysis. The results of
microarray analysis were confirmed by stem-loop real-time PCR
and Northern blot analyses. Among a number of miRNAs with
significantly altered expression levels, we focused on the less well
studied miR-22 in hepatocytes.
MicroRNA-22 is a highly evolutionarily conserved microRNA
present in various primary tissues and cell lines [12]. Recently,
miR-22 was found to be involved in various signaling pathways,
including estrogen, PTEN/AKT, and c-Myc [13–15]. Ectopic
overexpression of miR-22 inhibits cell proliferation and induced
G1 cell cycle arrest, while a lower expression level of miR-22
correlated with a higher degree of tumorigenicity in human
hepatocellular carcinoma patients [15–17]. Previous studies
reported the potential roles of miR-22 in heart and muscle
[14,16]. In this study, we took an approach of proteomic analysis
to identify direct or indirect targets of miR-22 in transdiffer-
entiated hepatocytes. One of the potential targets of miR-22 that
we identified here is parathymosin.
Parathymosin is a small nuclear protein that can physically
interact with glucocorticoid receptors (GR) and histone H1,
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observed here the reduction of parathymosin mRNA and protein
levels in AR42J-B13 cells treated with Dex/OSM or with a miR-
22 expression vector. We also demonstrated here that miR-22
could reduce the expression of parathymosin by binding to two
predicted sites at the 39 UTR of parathymosin gene. Treatment of
antagomiR-22 (anti-miR22) resulted in an increased expression of
the reporter containing the 39UTR of parathymosin. In addition,
anti-miR treatment can result in increased expression of
parathymosin mRNA or protein in rat AR42J-B13 cells and
human HepG2 and Huh7 cells. Taken together, we identified
miR-22 as a microRNA species highly elevated in transdiffer-
entiated hepatocytes. One of the potential targets of miR-22 is
parathymosin. Further studies of the relationships among miRNAs
and their targets should contribute to our understanding of hepatic
transdifferentiation in AR42J-B13 cells.
Results
MiRNA expression profiles during AR42J-B13 hepatic
transdifferentiation
To examine the expression profiles of miRNAs during Dex/
OSM induced AR42J-B13 transdifferentiation, we used chip-
based miRNA microarray analysis. By comparing the miRNA
expression profiles of AR42J-B13 cells before and after transdiffer-
entiation, we observed four major patterns of miRNA expression:
1) the majority of miRNAs were expressed at low levels, regardless
of the transdifferentiation status (data not shown). 2) Some
miRNAs, including let-7 family (let-a, -b and -c), miR-16, miR-
23b, miR-26, miR-31 and miR-375, were always highly expressed
either before or after transdifferentiation (data not shown). 3) We
identified 29 down-regulated miRNAs (Table 1). 4) We also
identified 13 up-regulated miRNAs with fold changes greater than
2 in two independent experiments (Table 2).
Among the 13 up-regulated miRNAs, miR-122a, miR-21, miR-
22 were the most enriched in transdifferentiated hepatocytes with
a fold change of ,70, ,20 and ,10, respectively (Table 2).
Relative to the up-regulated miRNAs (increased by 2 to 70 fold),
the magnitude of decrease in the down-regulated miRNAs was
modest (less than 7 fold). The results in Table 1 and 2 were further
validated by Northern blot (Fig. 1A and Figure S1) and stem-loop
real-time PCR analysis (Fig. 1B and 1C). In general, the fold
change of expression of abundant miRNAs, such as miR-122a,
miR-21, and miR-22, was much more pronounced in the stem-
loop PCR assay than the microarray assay due to the sensitivity
and linear range of the PCR assay.
Transdifferentiated AR42J-B13 cells are hepatocyte-like
based on the clustering analysis of miRNA expression
profiles between hepatocytes and non-hepatocytes
We investigated further by stem-loop real-time PCR analysis
that these three most abundant miRNA species in transdiffer-
entiated hepatocyte-like cells were indeed also highly expressed in
rat liver in vivo as well as hepatoma cell lines in vitro, including
Huh7 and Morris hepatoma 7777 (Q7 cells in [5]) (data not
shown). Such a miRNA expression signature has been well
documented in cancer profiling and classification [20]. Using these
hepatocyte and non-hepatocyte cell lines and primary tissues, we
performed unsupervised clustering analysis by selecting 7 down-
regulated miRNAs (miR-17-5p, miR-18a, miR-93, miR-106a,
miR-106b, miR-130b and miR-375) and 4 up-regulated miRNAs
(miR-21, miR-22, miR-122a and miR-182). The results revealed
that the transdifferentiated AR42J-B13 cells exhibited a miRNA
signature profile most closely related to hepatoma cell lines, such
as Q7 and Huh7 (Fig. 2). In part because of the very low level
expression of miR-122a, human hepatoblastoma cell line HepG2
was, to our surprise, clustered into non-hepatocytes.
Identification of miR-22 target by 2D-DIGE and LC/MS/MS
To focus on the less well studied miR-22, we attempted to
identify the potential targets of miR-22. We pooled AR42J-B13
cells stably transfected with pIRES2-EGFP-miR-22. The cloning
and construction of this miR-22 expression vector is as described
in the Experimental Procedures. Our miR-22 sequences are
identical to those available in the miR database (Figure S2). These
transfected cells were enriched by cell sorter on EGFP positive
cells and followed by G418 selection. Mature miR-22 in these
stably transfected cells were significantly higher than that of the
vector control by Northern blot and real-time PCR (Fig. 3A and
B). To identify the targets of miR-22, we first performed 2D-DIGE
Table 1. Decreased miRNA expression profile of AR42J-B13
cells after transdifferentiation by miRNA microarray*.
miRNA Fold of decrease
Exp1 Exp2
miR-181b 7.14 5.00
miR-106a 6.25 5.56
miR-130b 6.25 5.56
miR-17-5p 6.25 5.88
miR-93 5.88 5.88
miR-106b 5.56 5.00
miR-15b 5.56 3.70
miR-25 5.56 3.70
miR-335 5.56 4.00
miR-138 5.00 3.03
miR-181a 4.55 4.17
miR-18a 4.35 2.86
miR-181d 4.00 2.70
miR-19b 3.70 3.85
miR-20a 3.70 2.78
miR-7i 3.24 2.28
miR-342 3.23 3.03
miR-130a 3.13 2.63
miR-20b 3.13 2.56
miR-27b 3.13 3.03
miR-31 3.13 2.33
miR-672 3.03 2.50
miR-375 2.94 3.13
let-7d 2.86 2.38
miR-16 2.70 2.94
miR-92 2.56 2.78
miR-99a 2.44 2.78
miR-99b 2.22 2.44
miR-23b 2.17 2.38
*MicroRNA microarray was used to profile differential miRNA expression during
AR42J-B13 transdifferentiation. The fold of decrease represented the reduction
of miRNAs after transdifferentiation. Results from two independent microarray
analysis with fold changes greater than 2 were shown in the Table.
doi:10.1371/journal.pone.0034116.t001
microRNA-22 and Parathymosin
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overexpressing miR-22. Three differentially expressed features
were subjected to LC/MS/MS analysis for protein identification.
Four proteins with altered expression in miR-22 stably overex-
pressing cells were identified (Fig. 4A). Parathymosin (Ptms), and
ubiquitin carboxyl-terminal hydrolase isozyme L3 (Uchl3) were
reduced in expression, while vesicle-associated membrane-associ-
ated protein B (Vapb) and adenylate kinase isoenzyme 2 (AK2)
were increased. To validate a target of miR-22, we chose to focus
on parathymosin. Transient transfection of miR-22 into AR42J-
B13 cells resulted in a high level of miR-22 by stem-loop RT-PCR
(Fig. 4B), and approximately 10-fold reduction of parathymosin
protein by Western blot analysis (Fig. 4C).
Reduction of parathymosin mRNA and protein by
treatments of Dex/OSM induction or miR-22
overexpression
To confirm the results from proteomic analysis in Fig. 4A, we
performed Western blot analysis using anti-parathymosin antibody
and whole cell lysates from AR42J-B13 cells, with or without Dex/
OSM induction, as well as with or without stable transfection using
a pIRES-miR-22 expression vector (Fig. 5A). A similar degree of
reduction of parathymosin protein in AR42J-B13 cells was
detected by comparing Dex/OSM induction with miR-22
overexpression side-by-side. In addition to the parathymosin
protein level, we also measured the parathymosin mRNA levels of
AR42J-B13 cells treated with Dex/OSM or with miR-22
overexpression, by real time PCR analysis (Fig. 5B and 5C). In
both cases, the mRNA levels of treated samples were reduced to
approximately 70% of the untreated controls.
Bioinformatic analysis of the 39 UTR of parathymosin
mRNA
The 39UTR region of parathymosin is highly conserved across
human mouse and rat (Figure S3). The reduction of parathymosin
could be caused by a direct or indirect effect from miR-22. In the
former case, miR-22 could directly bind to the 39 UTR of
parathymosin mRNA, and mediate its suppression of gene
expression. In the latter case, miR-22 could mediate its effect by
influencing other cellular genes which in turn reduced the
expression of parathymosin. In theory, direct and indirect effects
are not mutually exclusive. To distinguish between the potential
direct and indirect effects from miR-22, we first conducted
computer-aided analysis. Some target prediction algorithms, such
as TargetScan 5.2 [21] and miRanda [22], predicted no miR-22
binding sites on the parathymosin 39UTR with a free energy less
than 220 kcal/mol (data not shown). It therefore appears that the
effect of miR-22 on parathymosin could be mediated through an
indirect mechanism. However, other software programs, such as
RNA Hybrid [23], predicted two miR-22 binding sites at the
39UTR of parathymosin (free energy less than 220 kcal/mol).
These predicted target sites are highly conserved in human and
rodents (Figure S3). As shown in Fig. 6A and 6B, there is no
perfect match between the putative seed region of miR-22 and the
two predicted target sites on parathymosin 39UTR. These features
suggest that the predicted target sites of miR-22 at the 39UTR of
parathymosin may not be convincing. On the other hand, it is well
known in the literature that some of the socalled unconventional
target sites for miRNA binding could involve some imperfect
match of base pairing between the seed region and the target site
[24–26].
MiR-22 inhibited the expression of parathymosin
through the 39UTR binding sites
To experimentally test the possibility of any unconventional
target sites of miR-22 on the 39 UTR of parathymosin, we
performed the reporter assay using a DsRed reporter containing
the parathymosin 39UTR. The relative mean fluorescence
intensity (MFI) was calculated by FACS analysis. Comparing with
the pIRES vector control, miR-22 inhibited the reporter
expression by about 50%. We next performed site-directed
mutagenesis at each predicted miR-22 target sites at the 39
UTR of parathymosin. Two nucleotide changes were introduced
into each predicted binding sites (Fig. 6B). The DsRed-
parathymosin 39 UTR reporter plasmid (DsRed-ParaT) was
cotransfected with the pIRES vector control plasmid or pIRES-
miR-22 expression plasmid into AR42J-B13 cells. As shown in
Fig. 6C, the wild type reporter (DsRed-ParaT) activity was
subjected to the suppression effect from pIRES-miR-22 (open bar).
The effect appeared to be modest, yet highly reproducible.
Mutations at a single miR-22 binding site (DsRed-ParaT-mu1 or
DsRed-ParaT-mu2) did not abolish the suppression effect from
pIRES-miR-22 on the reporter activity. However, mutations on
both putative binding sites of the reporter plasmid (DsRed-ParaT-
mu1/2) resulted in a reporter activity comparable to that of
cotransfection with the pIRES control (solid bar) (Fig. 6C). The
results of the reporter assay in Fig. 6C was confirmed by a real-
time PCR assay for the mRNA level of DsRed reporter with either
a wild type or a mutant parathymosin 39UTR (Fig. 6D). The
results indicated that miR-22 could reduce DsRed mRNA levels
through its binding site on the parathymosin 39UTR (Fig. 6D).
To further validate whether miR-22 can directly bind to the
39UTR of parathymosin to suppress its expression, we generated
compensatory mutations on the putative seed region of miR-22
that can restore the sequence complementarity to the mutated
binding site 2 (Fig. 7A). Indeed, the pIRES-miR-22 compensatory
mutant 2 restored the suppression effect on the reporter activity of
39UTR mutant 2 and mutant 1/2 (Fig. 7B).
Table 2. Increased miRNA expression profile of AR42J-B13
cells after transdifferentiation by miRNA microarray*.
miRNA Fold of increase
Exp1 Exp2
miR-122a 76.92 74.07
miR-21 23.42 22.37
miR-22 16.16 11.35
miR-422b 4.69 2.92
miR-30b 3.47 2.48
miR-29a 3.4 3.13
miR-182 3.28 3.29
miR-29c 3.1 2.34
miR-101b 2.79 2.04
miR-192 2.39 2.26
miR-29b 2.34 2.01
miR-30d 2.33 2.08
miR-194 2.24 2.10
*MicroRNA microarray was used to profile differential miRNA expression during
AR42J-B13 transdifferentiation. The fold of increase represented the enrichment
of miRNAs after transdifferentiation. Results from two independent microarray
analysis with fold changes greater than 2 were shown in the Table.
doi:10.1371/journal.pone.0034116.t002
microRNA-22 and Parathymosin
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antagomiR-22
Next, we asked whether knockdown of miR-22 could increase
the reporter activity. We applied the locked nucleic acid (LNA)
technology to deliver anti-miR-22 into a rat hepatoma cell line Q7
[5] to knockdown the endogenous level of miR-22. Consistent with
results in Fig. 6 and 7, we observed the elevation of the
cotransfected DsRed reporter activity (Fig. 8A). The efficacy of
LNA anti-miR-22 was evaluated in Q7 cells by real-time PCR
analysis of the miR-22 RNA level (Fig. 8B). Similarly, LNA
knockdown of miR-22 in transdifferentiated AR42J-B13 cells
resulted in a significantly increased level of parathymosin mRNA
(Fig. 8C).
An in vivo inverse correlation between miR-22 expression
and the parathymosin mRNA level
Consistent with the results in Fig. 6, 7, 8, we found an inverse
correlation between parathymosin mRNA and miR-22 levels
Figure 1. Northern blot and stem-loop real-time PCR analysis of differentially expressed miRNAs before and after
transdifferentiation of AR42J-B13 cells. The differentially expressed miRNAs identified by miRNA microarray were confirmed by miRNA
Northern blot (A) and stem-loop real-time PCR analysis (B and C). Total RNA extracted from Dex/OSM treated AR42J-B13 cells (7 Days) and mock
controls were used for Northern blot analysis using antisense probes against down-regulated miRNAs (miR-93, miR-106b and miR-130b) and up-
regulated miRNAs (miR-21, miR-22, miR-122a and miR-182). The relative fold changes of stem–loop real-time PCR were normalized to AR42J-B13 cells
before transdifferentiation and U6 was used as a loading control. (*** P,0.001).
doi:10.1371/journal.pone.0034116.g001
microRNA-22 and Parathymosin
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PCR and stem-loop PCR analyses (Fig. 9A and 9B). For example,
miR-22 is most abundant in muscle and heart, while parathymosin
is the least abundant in muscle and heart. However, such an
inverse correlation does not always hold true (e.g., pancreas). As
shown in Fig. 9C, computational analysis of the promoter region
of miR-22 predicts several binding sites for transcription factors,
including HNF-4a, myogenin, and pax-4. Therefore, the high
abundance of miR-22 in liver, muscle, and heart is most likely
driven by these tissue specific transcription factors [8,27]. Indeed,
we found both pri-miR-22 and mature miR-22 were increased in
expression, which correlated with HNF-4a mRNA level during
AR42J-B13 transdifferentiation (Figure S4A). Pax-4 is a negative
transcription factor which is transiently expressed during the
embryonic development of pancreas [28]. Pax4 is not expressed in
un-induced AR42J-B13 cells and only slightly induced after
transdifferentiation (Figure S4B).
MiR-22 is neither necessary nor sufficient for
transdifferentiation
As shown in Table 1 and 2, expression of many microRNAs
changed upon transdifferentiation. It is also well known that each
microRNA has a potential to target hundreds of genes [6].
Therefore, it is difficult to predict which microRNA species or
which target genes might play a regulatory role in programming
transdifferentiation. As a preliminary attempt to address this issue,
we asked whether transdifferentiation can be perturbed by
knocking down the endogenous miR-22 (Fig. 10A–10D) or by
overexpressing parathymosin (Fig. 10E–10H). We introduced
LNA-anti-miR-22 into a B13-1 cell line and monitored the
expression of transdifferentiation markers in the transfected
culture of B13-1 cells. This B13-1 cell line was established
previously by stable transfection of AR42J-B13 cells with an HBV
genome [4]. HBV-encoded surface antigen (HBsAg) and e antigen
(HBeAg) can be released into the medium upon transdifferentia-
tion. Using HBsAg and HBeAg as surrogate markers of
transdifferentiation, we observed no difference in HBeAg
secretion, when B13-1 cells were transfected with anti-miR-22
before Dex/OSM treatment (Fig. 10A; Experimental Procedures).
In contrast, we observed a reproducible difference in the secreted
amount of HBsAg by ELISA analysis (Fig. 10B). To further
investigate this apparent contradiction between HBsAg and
HBeAg, we examined other transdifferentiation markers, includ-
ing albumin and alpha1-anti-trypsin (Fig. 10D), as well as HNF4a
Figure 2. The miRNA expression profile of transdifferentiated AR42J-B13 cells is most closely related to those of hepatoma cell
lines by clustering analysis. The expression levels of miRNAs of various hepatoma cell lines (HepG2, Huh7 and Q7 cells), primary tissues (rat
spleen, pancreas and liver), and NIH3T3 cells, were measured by stem-loop real-time PCR analysis. Clustering analysis using Genespring V11.0
software was performed by the normalization of the expression level from each sample relative to that of AR42J-B13 cells. Both up-regulated miRNAs
(miR-21, miR-22, miR-122a and miR-182) and down-regulated miRNAs (miR-17-5p, miR-18a, miR-93, miR-106a, miR-106b, miR-130b and miR-375) were
chosen as a parameter for comparison.
doi:10.1371/journal.pone.0034116.g002
microRNA-22 and Parathymosin
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studies suggest that the reduction of endogenous miR-22 has no
significant effect on transdifferentiation in general, albeit a minor
effect on HBsAg was noted (Fig. 10A; see Discussion).
Similarly, we asked whether parathymosin has any effect on
hepatic transdifferentiation of B13-1 cells. As shown in Fig. 10E–
10H, we detected no apparent effect on the expression of both
viral and cellular transdifferentiation markers, when B13-1 cells
were transfected with a parathymosin expression vector before
Dex/OSM treatment (Material and Methods). The daily expres-
sion of the exogenous parathymosin protein was monitored on day
1 to day 7 post-induction by Western blot analysis (Fig. 10G).
As shown in Fig. 10, we have demonstrated that reduction of
miR-22 or expression of parathymosin has no major effect on
Dex/OSM-induced transdifferentiation. While this result strongly
suggests that miR-22 is not necessary for transdifferentiation, it
remains unclear if miR-22 expression could be sufficient for
transdifferentiation. To address this issue, we cotransfected
AR42J-B13 cells with a HBV replicon and pIRES-miR-22
without treatment of Dex/OSM, and detected no HBsAg in the
medium by ELISA (data not shown). The same negative result in
HBsAg ELISA was obtained when the same cotransfection
experiment was performed by using B13-1 cells without Dex/
OSM (data not shown). Taken together, miR-22 does not appear
to be either necessary or sufficient for transdifferentiation of
AR42J-B13 cells.
MiR-22 can target parathymosin in human hepatocytes
So far, our studies on miR-22 and parathymosin have been
based on the rat cells, such as Q7, AR42J-B13 and its derived B13-
1 cells. To demonstrate the generality of our studies, we extended
our research to human hepatoma cell lines Huh7 and HepG2. As
shown in Fig. 11, we examined by Western blot analysis the
expression of parathymosin in HepG2 and Huh7 cells transfected
with LNA-anti-miR-22 or LNA-scramble control, respectively.
Indeed, treatment with anti-miR-22 can result in elevated
expression of parathymosin protein in both HepG2 and Huh7
cells.
In summary, we used miR-22 as a model system to examine the
control of gene expression during hepatic transdifferentiation of
AR42J-B13 cells.
Discussion
We profiled the microRNA expression of rat AR42J-B13 cells
before and after transdifferentiation into hepatocytes (Table 1 and
2). The expression of miR-22 was increased by more than 100-fold
after hepatic transdifferentiation, as measured by real-time PCR
analysis (Fig. 1B). To date, unlike miR-122a, miR-22 in
hepatocytes has been less well studied [21,29]. To understand
better the biology of miR-22, we identified parathymosin as a
potential target of miR-22 (Fig. 4A). We found that miR-22 could
reduce the protein and mRNA expression of parathymosin (Fig. 4,
5, 6, 7, 8, 9, 10, 11). The biological significance of miR-22 and
parathymosin is discussed below.
Reduction of gene expression by miR-22
The reduction of the DsRed reporter mRNA in the transient
transfection system (Fig. 6D) is consistent with the reduction of
parathymosin mRNA in miR-22 overexpressing cell lines by real-
time PCR analysis (Fig. 5C). These results were also confirmed by
the microarray analysis (fold change 0.7) (data not shown). In
addition to parathymosin, other cellular proteins, such as ubiquitin
carboxyl-terminal hydrolase isozyme L3 (Uchl3), were also
reduced in expression (Fig. 4A).
Translational suppression vs. mRNA degradation
MicroRNAs can fine tune the gene expression by translational
suppression or by promoting degradation of targeted mRNAs
[30,31]. As shown in Fig. 4C and Fig. 5A, stable transfection with
pIRES-miR-22 can reduce the protein expression of parathymosin
by 5–10 folds in Western blot analysis. However, the 5–10 fold
effect of miR-22 on the protein expression of parathymosin
(Fig. 4C) is much greater than its less than 2-fold effect on the
mRNA level (Fig. 5C). Therefore, it is possible that miR-22 could
affect both mRNA stability and protein translation of parathy-
mosin through its direct targeting at the 39UTR of parathymosin.
Figure 3. Ectopic overexpression of miR-22 in AR42J-B13 cells was analyzed by Northern blot (A) and stem-loop real-time PCR
analysis (B). (A) pIRES is the empty vector control. pIRES-miR-22 is the miR-22 expression vector. (B) B13-pIRES is the AR42J-B13 cells stably
transfected with the pIRES vector control, while B13-pIRES-miR-22 is the AR42J-B13 cells stably transfected with the miR-22 expression vector.
MicroRNA-93 was used as a negative control. (***, p,0.001).
doi:10.1371/journal.pone.0034116.g003
microRNA-22 and Parathymosin
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effect on the protein expression of parathymosin. For example,
miR-22 could affect the expression of another gene(s) which in
turn affects the expression of parathymosin.
Elevation of gene expression by miR-22
As shown in Fig. 4A, the protein expression of vesicle-associated
membrane-associated protein B (Vapb) and adenylate kinase
isoenzyme 2 (AK2) were increased in cells overexpressing miR-22.
Figure 4. 2D-DIGE analysis identified differentially expressed proteins in miR-22 overexpressing AR42J-B13 cells. Protein lysates of
pooled B13-pIRES or B13-pIRES-miR-22 cells were labeled with Cy3 and Cy5, respectively (Experimental Procedures). Three differentially expressed
features, Features A, B and C, were picked up for identification by LC-MS/MS. Proteins with altered expression were indicated by arrows. The
candidate proteins identified were listed in the table below the image. Parathymosin protein was down-regulated as assayed by 2D-DIGE (A) and
Western blot analysis (C) in AR42J-B13 cells stably transfected with pIRES-miR-22. The miR-22 expression level in transiently transfected AR42J-B13
cells was measured by stem-loop real-time PCR (B). (***, p,0.001).
doi:10.1371/journal.pone.0034116.g004
microRNA-22 and Parathymosin
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stimulate HCV replication in human hepatoma Huh7 cells. This
positive effect is mediated through direct binding of miR-122a to
two different target sites near the 59 end of HCV RNA genome
[32]. The detailed mechanism of the increased protein expression
of Vapb and AK2 by miR-22, directly or indirectly, remains to be
investigated in the future.
Solo vs. clustering miRNA
The pattern of coordinated reduction in expression of miR-25,
miR-93, and miR-106b (Table 1) is due to the clustering of these
three miRNA genes at intron 12 of Mcm7 on chromosome 12. As
such, they share the same promoter and are processed from the
same precursor mRNA of Mcm7 [33,34]. Similarly, genes
encoding for miR-192 and miR-194 are clustered on chromosome
1, and could explain their coordinated increase in expression
(Table 2). The genes encoding for miR-17-1/miR-17-5p, miR-
18a, miR-19a, miR-20a, miR-19b-1, and miR-92a-1 are clustered
on chromosome 15 [35]. While the reduction in expression of
miR-17-5p, miR-18a, miR-20a, and miR-92 were well coordinat-
ed in transdifferentiation, the expression of miR-19a was not
concordant with its neighboring microRNA genes. In contrast to
the clustering miRNA genes as mentioned above, some solo
microRNAs, such as miR-22 on chromosome 10 [35] and miR-
122a on chromosome 18, can be expressed independently from
the other miRNAs.
Transcription factors and biogenesis of miR-22
As shown in Fig. 9C, the upstream sequences from the miR-22
gene contain two HNF-4a, one Pax-4, and one myogenin binding
motifs. Presumably, the expression of miR-22 is driven by HNF-
4a, which is highly abundant in transdifferentiated AR42J-B13
cells [3,4]. As shown in Table 2, we found increased expression of
liver specific miRNAs in transdifferentiated hepatocytes, including
miR-122a, miR-21, miR-22, miR-182, miR-29 and miR-30. By
computer software prediction, HNF-4 binding sites are also
present in the 59 upstream regions of miR-21, miR-30b and
miR-30d. Similarly, the binding site of a liver specific transcription
factor HNF-1 can be predicted in the 59 upstream region of miR-
122a, miR-192 and miR-194-2 [9,27,36]. It is worth mentioning
here that the expression kinetics of primary miR-22 RNA
precursor paralleled to that of mature miR-22, suggesting the
lack of control at the level of posttranscriptional processing (Figure
S4). Taken together, we speculate that these upregulated
expressions of miRNAs in transdifferentiated hepatocytes are
mainly orchestrated by liver specific transcription factors, such as
HNF-1 and HNF-4a.
Parathymosin biology
Parathymosin is a highly conserved small acidic nuclear protein.
It is widely distributed in mammalian tissues (Fig. 9;[19,37]). It can
bind to glucocorticoid receptor as a coactivator [18,19]. In
addition, it can also affect the binding of histone H1 and
Figure 5. Reduction of parathymosin mRNA and protein levels were observed in AR42J-B13 cells treated with Dex/OSM or a miR-22
expression vector. (A) Reduced expression of parathymosin protein in AR42J-B13 cells was induced by Dex/OSM treatment (B13+DM) or by stable
expression of miR-22 using Western blot analysis. (B & C) The expression of parathymosin mRNA was reduced to approximately 70% level in Dex/OSM
induced AR42J-B13 cells (B), and in the stably transfected AR42J-B13 cells overexpressing miR-22 (C). The mRNA level was measured by real-time PCR
analysis (***, p,0.001).
doi:10.1371/journal.pone.0034116.g005
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involved in chromatin remodeling and thus can regulate gene
expression epigenetically [18]. Although parathymosin is predom-
inantly localized in the nucleus, some studies also reported that it
can be shuttling between nucleus and cytoplasm depending on the
cell density and differentiation status [38]. Transdifferentiation of
AR42J-B13 cells can be induced by Dex treatment which is a
glucocorticoid hormone. Therefore, we speculate the possibility of
Figure 6. The suppression effect of miR-22 on the expression of parathymosin depends on the predicted miR-22 target sites at the
39UTR of parathymosin. (A) RNA Hybrid software predicted two miR-22 binding sites, designated as ‘‘1’’ and ‘‘2’’ in the cartoon, at the 39UTR of
parathymosin with free energy less than 220 kcal/mol. The reporter plasmid was engineered by fusing DsRED with the rat parathymosin 39UTR. (B)
Site-directed mutagenesis at the predicted miR-22 binding sites of the parathymosin 39UTR were illustrated. Two nucleotide substitutions were
introduced into each of the two predicted binding sites. The arrows indicate the mutation sites at the 39UTR of parathymosin. The sequences at the
39UTR of parathymosin were changed from 59-CU-39 to 59-GA-39 in mu1, and from 59-GG-39 to 59-CC-39 in mu2. (C) The reporter assay was performed
by transient cotransfection of AR42J-B13 cells with the plasmid of a DsRED reporter containing various wild type and mutant parathymosin 39UTR,
and plasmid pIRES-miR-22. The mean fluorescence intensity (MFI) of DsRED was measured by FACS analysis gated on DsRED positive cells. The
relative MFI was calculated by normalization to the pIRES control. Mutations at both predicted sites have an additive effect on miR-22 mediated
silencing (***, p,0.001; **, p,0.005; ns, not significant). (D) The reduction of the DsRED reporter mRNA, containing wild type parathymosin 39UTR,
was abolished by mutations at the predicted binding sites of miR-22. Real-time PCR analysis on DsRED mRNA was performed by using the same
reporter assay as described above in Fig. 6C. (*, p,0.5).
doi:10.1371/journal.pone.0034116.g006
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responsive genes.
miR-22 is neither necessary nor sufficient for
transdifferentiation
MiR-22 is not likely to be required for Dex/OSM induced
transdifferentiation, since we observed no apparent effect on
several transdifferentiation markers by transfecting LNA-anti-
miR22 or by overexpressing parathymosin in B13-1 cells (Fig. 10).
Nor is miR-22 sufficient for transdifferentiation in the absence of
Dex/OSM, as we observed no detectable HBsAg when HBV was
cotransfected with the miR-22 expresssion vector into AR42J-B13
cells (data not shown). Intriguingly, while we observed no
significant effect on most transdifferentiation markers by reducing
the endogenous miR-22 (Fig. 10B, 10C, and 10D), we detected
small, yet reproducible, increase of HBsAg by ELISA after anti-
miR22 treatment (Fig. 10A). Further analysis by Southern blot
Figure 7. Compensatory mutations of miR-22 restored the repression effect of miR-22 on the 39UTR of a parathymosin reporter
containing a mu2 target site. (A) Compensatory mutation from 59-CC-39 to 59-GG.-39 at the predicted seed sequences of miR-22. (B) Reporter gene
assay was performed by co-transfection into AR42J-B13 cells with the various DsRED reporter plasmids, containing various wild type and mutant
parathymosin 39UTR, and pIRES-miR-22 containing the compensatory mutation. FACS analysis was performed as in Fig. 6. (***, p,0.001; ns, not
significant).
doi:10.1371/journal.pone.0034116.g007
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not shown).
Downregulated microRNAs in transdifferentiated
hepatocytes
It is known that Dex treatment can cause growth arrest which
precedes transdifferentiation [3,4]. As shown in Table 1, both
miR-93 and miR-130b were reduced in transdifferentiated
hepatocytes. Interestingly, Yeung et al. reported that miR-93
and miR-130b have a potential to target tumor suppressor protein
p53-induced nuclear protein 1 (TP53INP1) in HTLV-1 infected/
transformed cells [39]. TP53INP1 is a stress-induced protein and
plays a role in controlling cellular proliferation and apoptosis [40].
Therefore, we speculate here that downregulation of miR-93 and
miR-130b can result in elevated expression of tumor suppressor
TP53INP1, which in turn can cause growth arrest of AR42J-B13
cells leading to transdifferentiation. Consistent with this specula-
tion, our microarray data revealed that the cell cycle-related
pathway is ranked the first pathway among all the downregulated
genes, including cyclin A2 and cyclin B2, upon Dex/OSM
treatment (unpublished results). Further investigation of micro-
RNAs could help elucidate the mechanism of hepatic transdiffer-
entiation.
Materials and Methods
Cell culture and transfection
AR42J-B13 cells [3] and human hepatoma cell lines Huh7 [41],
HepG2 [42] were obtained from laboratories as cited here. These
cell lines were maintained in Dulbecco’s modified Eagle’s medium
Figure 8. LNA-based antagomiR-22 increased parathymosin 39UTR reporter activity in a hepatoma cell line Q7 by knockdown
endogenous miR-22. (A) The reporter assay was conducted by co-transfection of DsRED-parathymosin 39UTR with LNA-antagomiR-22 in Q7 cells
using Lipofectamine 2000. Reporter activity was significantly increased when 100 pmol of LNA-anti-miR-22 was used. (B) Different concentrations of
LNA-antagomiR-22 were used to knockdown the endogenous miR-22 expression level, which was measured by stem-loop real-time PCR.
(***, p,0.001) (C) Parathymosin mRNA was increased significantly by stem-loop real-time PCR, when transdifferentiated AR42J-B13 cells were treated
with LNA-anti-miR-22. (*, p,0.5).
doi:10.1371/journal.pone.0034116.g008
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(Hyclone) at 37uC in the presence of 5% CO2. The Genejuice
(Novagen) and lipofectamine2000 (Invitrogen) transfection proce-
dure was according to manufacturer’s instructions.
Induction of transdifferentiation. AR42J-B13 cells were
cultured in DMEM (Dulbecco’s modified Eagle’s medium).
Dexamethasone (Dex) and oncostatin M (OSM) were purchased
from Sigma and R&D systems, respectively. To induce
transdifferentiation, Dex and OSM were added at working
concentrations 1 mM and 10 ng/ml, respectively. The medium
of the cells treated with Dex/OSM were replenished every 2 days
and maintained for 7 days before assay.
Rno-miR-22 cloning. The sequence of miR-22 was retrieved
from Ensembl database and mirbase. The following primers were
used to clone the full length stem-loop of miR-22: rno-miR-22-
F:59-TCAGCTGTCCTCTCCCTCAT-39 and rno-miR-22-R:59-
AGTGTCCCCTTTCCCTGAGT-39. The PCR product was
sub-cloned from TA cloning vector (RBC) to pIRES2-EGFP
Figure 9. An inverse correlation between the expression levels of parathymosin mRNA and miR-22 was observed in most rat
primary tissues. Real-time PCR quantified parathymosin mRNA expression profile in various rat primary tissues, including cerebellum, cerebrum,
eye, fat, muscle, pancreas, kidney, heart, lung, spleen, thymus and liver. AR42J-B13 cells with or without Dex/OSM induced transdifferentiation were
included as references. The relative mRNA level of parathymosin was normalized to that of untreated AR42J-B13 cells (A). The expression of miR-22 in
these tissues and cells were measured by stem-loop real-time PCR (B). The binding sites of transcription factors on the miR-22 promoter are predicted
by the Transfac software (27) and presented in the schematic illustration (C).
doi:10.1371/journal.pone.0034116.g009
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reversed clones were confirmed by sequencing.
Pooled stable miR-22 overexpressing cell lines.
Approximately 1610
6 AR42J-B13 cells were transiently transfected
by 3 mg plasmid DNA (pIRES2-EGFP-miR-22) with Genejuice
(Novagen). The transfection efficiency was monitored by
flowcytometry analysis. Following G418 selection for three weeks,
the remaining colonies were pooled together and sorted again by
FACS. Only EGFP positive cells were collected. These pooled stable
cell lines were then maintained for 3 weeks before assay.
miRNA microarray (Ambion). miRNAs were extracted by
mirVana
TM miRNA Isolation Kit, and subsequently enriched by
flashPAGE
TM Fractionator. Fifty mg of total RNA were subject to
electrophoresis in pre-cast gel and the RNA species less than 40 nt
were eluted from the gel. The elution was further clean-up and
concentrated by flashPAGE
TM Reaction Clean-Up Kit. After
spin-vac drying, the enriched small RNA was labeled with Ambion
mirVana
TM miRNA Labeling Kit and subject to microarray
analysis. Small RNAs containing mature miRNAs were labeled
with the mirVana
TM miRNA labeling kit and hybridized to
mirVana
TM miRNA Bioarrays v.9.2 according to the vendor’s
protocol. Version 9.2 of mirVana microarray coincides with
version 9.2 of miRBase sequence database [35], containing human
(471 miRNAs), mouse (380 miRNAs) and rat (238 miRNAs)
probes. Microarrays were scanned with a GenePix 4000B scanner
(Axon instruments, GenePix software version 5.0). The data was
imported into Genespring (Agilent) for normalization and
clustering analysis.
Real-time PCR analysis. cDNA was synthesized by High
Capacity cDNA Reverse Transcription kit (Applied Biosystem)
according to manufacturer’s manual. Briefly, 10 mg RNA was
reverse transcribed into cDNA using random primers at 37uC for
120 minutes. The cDNA was then diluted 100 times for real-time
PCR analysis using Power SYBR Green PCR master mix (Applied
Biosystem). The real-time PCR was performed using default
condition in 20 ml reactions by Applied Biosystems 7500 Real-
Time PCR System and data were analyzed by relative
quantification methods (DDCt methods) using 7500 software
V2.0.1.
Stem-looped miRNA real-time PCR. Taqman RT and
stem-loop real-time assay were purchased from Applied
Biosystems. miR-22 (assayID: 000398), miR-122a (assayID:
002245) and miR-93 (assayID: 001090) were used according to
manufactory’s manual. Briefly, 100 ng RNAs were reverse
transcribed by specific stem-loop primer and further analyzed by
Taqman assay real-time PCR using default setting. U6 snRNA
(assayID: 001973) was used as an internal loading control. Data
were analyzed by Applied Biosystems 7500 Real-Time PCR
System and 7500 software V2.0.1.
miRNA Northern blot analysis. 20 mg of total mRNA per
sample extracted by Trizol (Invitrogen) were mixed with equal
volume of denaturing gel loading buffer (which contains 95%
formamide, 18 mM EDTA, 0.025% xylene cyanol, 0.025%
bromophenol blue and 0.025% SDS). The RNA samples were
denatured by heat at 95uC for 5 min and place on ice for at least
2 minutes prior to electrophoresis. After denaturation, the RNA
was resolved by 15% denaturing polyacrylamide gel (with 8 M
urea in Tris-borate buffer, which contains 90 mM Tris, 90 mM
Boric acid and 2 mM Na2EDTA with pH 8.3 at 25uC) at 15 mA
for approximately 1 hour. The gel was then transferred to nylon
Figure 10. The potential effect of parathymosin or miR22 on the transdifferentiation of AR42J-B13 cells. (A) Similar levels of HBV e
antigen (HBeAg) were detected in the media of B13-1 cells transfected with LNA anti-miR22 vs. a LNA scramble control. (B) Increased secretion of HBV
surface antigen (HBsAg) was detected by ELISA in the medium of B13-1 cells transfected with LNA anti-miR22. (C) The reduction of the endogenous
level of miR-22 in B13-1 cells after LNA anti-miR-22 treatment, was measured by real time PCR. (D) Treatment of B13-1 cells with LNA anti-miR22
resulted in no significant effect on transdifferentiation markers of alpha1-antitrypsin and albumin by Western blot analysis. (E & F) No significant
effect on secreted HBsAg and HBeAg was detected by ELISA in B13-1 cells transfected with a parathymosin (PTMS) expression vector. (G) A time
course of the gradual decrease of parathymosin protein in B13-1 cells was conducted by Western blot analysis. B13-1 cells were transfected with a
vector control (upper panel) or a parathymosin expression vector (lower panel) prior to Dex/OSM induction. (H) Transdifferentiation markers of
albumin and alpha1-antitrypsin were measured by Western blot analysis, using B13-1 cells transfected with a parathymosin expression vector or a
control vector pCDNA prior to Dex/OSM induction.
doi:10.1371/journal.pone.0034116.g010
Figure 11. Parathymosin can be targeted by miR-22 in human hepatoma cell lines Huh7 and HepG2. Increased expression of
parathymosin protein can be detected by Western blot when Huh7 and HepG2 cells were treated with LNA anti-miR-22 (Experimental Procedures).
doi:10.1371/journal.pone.0034116.g011
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30 minutes. The membrane was cross-linked by Ultraviolet
Crosslinkers (UVP) with 75006100 uj/cm
2 and then subjected
to pre-hybridization in (6 X SSC, 10X Denhart’s solution and
0.2%SDS with 100 mg of salmon sperm DNA). After pre-
hybridization, the membrane was hybridized with isotope-
labeled antisense miRNA probe (miRNA sequences were
retrieved from Sanger mirbase v16.0) at 37uC for 16 hours. The
membranes were washed at room temperature three times by
2xSSC with 0.5% SDS, and further washed at 42uC before
autoradiogram.
Protein preparation for 2D-DIGE analysis. AR42J-B13
cells stably transfected with either a miR-22 expression vector or a
vector only control were grown to 90% confluence in 10 cm dish.
After washing twice with 1X phosphate buffered saline (PBS), cells
were lysed by adding 500 ml lysis buffer (8 M urea, 4% CHAPS) to
each dish. The cells were scraped off from culture dishes and
transferred into eppendorf tubes, followed by three repeated
sonications (10-sec each time with a 5-sec interval). The cell lysates
were centrifuged at 13,000 rpm for 5 mins at 4uC and the
supernatants were transferred to new eppendorf tubes. The
protein concentrations were determined by BCA assay kit
(Thermo Scientific).
A total of 380 mg of protein lysates were used for CyDye
staining by the following procedures. First, the protein lysates were
adjusted to pH 8.5 by 1 M HEPES buffer and later labeled by
CyDye DIGE Fluor minimal dyes (GE) with the ratio of 8 pmole/
mg of protein at 4uC in dark. Rehydration loading was applied for
first dimension IEF for IPG strip (13 cm, pH 3–10, GE) under 30
volts, 12 hours. IEF condition was set as follows (Ettan IEFphor):
100 V for 30 mins, 250 V for 30 mins, 500 V for 30 mins,
1000 V for 30 mins, and 2000 V for 30 mins, 4000 V for 30 mins
and with gradient ramping to 8000 V to reach 50000 Vhr. The
second dimension was performed by GE SE600 system in 12%
SDS-PAGE at 200 volts for 4.5 to 5 hours. The gels were further
scanned by Typhoon using 2D-DIGE format (cy2:520 BP40;
cy3:580 BP30 and cy5:670 BP 30). 2D-DIGE Images were
analyzed by Decyder and the features were determined by default
setting of the software. Spots of interest were picked up by
automatic Ettan spot picker followed by manufacturer’s manual.
In-gel digestion. Picked spots of interest were washed in
25 mM NH4HCO3/50% ACN and let stand at room temp for
15–30 min. After wash, the gels were soaked in 100% acetonitrile
for 5 min and applied to spin-vac to completely dry. The dried gels
were then digested at 37uC for 16–24 hours in 10 mg/ml
sequencing grade trypsin (Promega) with 25 mM NH4HCO3
(pH 8.0). After digestion, the trypsin solution was transferred to a
new tube and combined with gel extractions containing 25–50 ml
of 50% ACN/5% TFA for 1 hour. The combined extracts were
dried by spin-vacuum centrifugation and subject to LC/MS/MS
analysis.
LC/MS/MS analysis. The peptide mixture was separated by
using reverse-phase capillary liquid chromatography (Magic
C18AQ, 75 mm 3 11 cm; Microm BioResources) at a flow rate
of 200 nl/min. The eluent was directly analyzed with ion-trap mass
spectrometry (Finnigan LCQ Deca XP; Thermo Scientific). A
survey scan followed by 3 collision induced dissociation events was
used. We performed the peptide identification using an in-house
version of Mascot v. 2.2 (Matrix science, London, United
Kingdom). The data sets were searched against Uni-Prot/Swiss-
Prot (400771 sequences) using the following constraints: only tryptic
peptides with up to two missed cleavage sites were allowed; 62D a
mass tolerances for MS and 60.8 Da mass tolerances for MS/MS
fragment ions. Oxidation (M) and carboxyamidomethylation (C)
were specified as variable modifications. Peptides were considered
as being identified if their Mascot individual ion score was higher
than 30 (p,0.01). The MS together with MS/MS spectra were
searched using the MASCOT 2.2 search engine (Matrix Science),
allowing one missed cleavage (trypsin). Precursor error tolerance
and MS/MS fragment error tolerance were set to 62D aa n d
60.8 Da. Only fully tryptic peptides and a MS/MS score above 30
were accepted for peptide identification. For protein identification
by shotgun proteomics, methionine oxidation and cysteine
carboxyamidomethylation were selected as variable modification.
Proteins with a total ionscore confidenceinterval percentage (CI %)
above 99% were considered positive identifications.
LNA anti-miR-22 knockdown of HepG2, Huh7 and B13-1
cell lines. Cells were cultured in 6-well plates in DMEM
(Dulbecco’s modified Eagle’s medium) to 70% confluence. One
day after seeding, cells were transfected with puromycin resistamt
plasmid (pTRE2pur) and LNA-scramble control or LNA anti-
miR-22 (Locked Nucleic Acid, Exiqon), using Lipofectamine 2000
(Invitrogen), according to the manufacturer’s instructions. Twelve
hours post-transfection, untransfected cells were removed by
puromycin treatment (2 mg/ml) for 2 days. Treated cells were
further incubated in the presence of 0.5 mg/ml puromycin for
another 2 days before harvesting for Western blot analysis. To
induce transdifferentiation of the HBV-transfected B13-1 stable
cell line [4], Dex/OSM were added as described earlier. The
expression of HBsAg and HBeAg were measured by ELISA using
HBsAg or HBeAg diagnostic kits (General Biologicals
Cooporation, Taiwan) according to the vendor’s protocols.
Antibodies. In general, primary antibodies were diluted 500–
1,000 fold for Western blot experiments. These primary antibodies
include rabbit polyclonal anti-albumin antibody (Santa Cruz),
rabbit polyclonal anti-alpha1-antitrypsin antibody (Sigma), rabbit
polyclonal anti-parathymosin antibody (Abcam) and mouse
polyclonal anti-tubulin antibody (GeneTex, Taiwan). Secondary
antibodies were diluted 5,000-fold for Western blot, including goat
polyclonal anti-mouse horseradish peroxidase (HRP) (Sigma), goat
polyclonal anti-rabbit- HRP (Santa Cruz).
Ethics Statement. All animal experiments were conducted
under protocols approved by Academia Sinica Institutional
Animal Care & Utilization Committee (ASIACUC). Research
was conducted in compliance with the principles stated in the Guide
for the Care and Use of Laboratory Animals, National Research Council,
1996. RNA samples extracted from rat tissues were a generous gift
from Dr. Yi-Shuian Huang at Academia Sinica, Taiwan.
Supporting Information
Figure S1 Northern blot analysis of miRNA of AR42J-
B13 (B13) and its HBV-producing stable clones, B13-1
and B13-28, during Dex/OSM induced transdifferentia-
tion (4). Mature miRNA of miR-93, miR-106b, miR-130b, miR-
21, miR-22 and miR-182 were differentially expressed after
transdifferentiation. U6 RNA was used as a loading control of
RNA.
(TIF)
Figure S2 Sequence alignment of cloned rat (rno) miR-
22 of AR42J-B13 origin with the reference genome from
Ensembl database (ENSRNOG00000035620). The primer
sequences for cloning and quantitative real-time PCR were listed.
One single nucleotide polymorphism (SNP) with an A to G change
is highlighted with an arrow, which is located outside the mature
miR-22 sequences.
(TIF)
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highly conserved at the 39UTR of parathymosin from
human, mouse and rat. The sequences at the 39 UTR of
parathymosin were retrieved from Ensembl database and miR-22
binding site prediction was performed by RNA Hybrid software.
The sequences of cloned 39UTR of rat parathymosin are identical
to that of the reference genome from Ensembl database
(ENSRNOG00000016386).
(TIF)
Figure S4 The expression levels of mature and primary
miR-22 RNAs were correlated with that of HNF4a during
hepatic transdifferentiation. (A) At different time points after
Dex/OSM treatment, mature miR-22 and primary miR-22
transcripts in transdifferentiating AR42J-B13 cells were measured
by real-time RT-PCR, respectively. (B) The expression levels of
HNF-4a, myogenin and pax-4 were measured by real-time PCR
after Dex/OSM treatment in AR42J-B13 cells.
(TIF)
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